BLAINJECTIONINJECTABLE
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ZIEXTENZO (pegfilgrastim-bmez) by Novartis. Approved for leukocyte growth factor [epc]. First approved in 2019.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZIEXTENZO (pegfilgrastim-bmez) is a pegylated granulocyte colony-stimulating factor (G-CSF) cytokine approved by BLA in November 2019. It works by stimulating the proliferation and differentiation of leukocytes to reduce the incidence of chemotherapy-induced neutropenia (CIN) and associated complications in cancer patients. As a long-acting G-CSF analog, it reduces the frequency of injections compared to standard filgrastim products. ZIEXTENZO is positioned as a convenient, extended-duration alternative in the well-established neutropenia supportive care market.
$0.0BPart D
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZIEXTENZO creates opportunities for oncology specialty field teams, brand managers focused on supportive care portfolios, and medical science liaisons engaging oncology providers and supportive care specialists. Success requires understanding chemotherapy regimens, hospital formulary dynamics, and clinician preferences around injection frequency and patient convenience. Currently zero open job positions are linked to this product in available data.
Company
Worked on ZIEXTENZO at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.